Connect your AI

Prime Medicine PRME Cash Cash Equivalents And Short Term Investments

Cash Cash Equivalents And Short Term Investments at other companies

Immix Biopharma, Inc.IMMX

——

PrecigenPGEN

——

Viridian Therapeutics, Inc.VRDN

——

Other financials

Income statement

Revenue$838.0K-61.6%

Operating income-$50.7M+3.3%

Net income-$49.1M+5.3%

EPS (diluted)-$0.28+30.0%

Balance sheet

Cash & equivalents$77.8M-26.6%

Total debt$114.5M-5.5%

Total equity$76.7M-28.3%

Total assets$294.7M-10.2%

Cash flow

Operating cash flow-$42.7M+12.6%

CapEx$214.0K-91.2%

Free cash flow-$42.9M+16.3%

Valuation

Market cap$574.36M+111%

Enterprise value$611.08M+113%

P/S124×+6.3×

Profitability

Operating margin-4,498.1%-1,134pp

Net margin-4,342.4%-1,099pp

FCF margin-3,607.4%—

Returns & leverage

Return on equity-216.1%+1,519pp

Debt / equity1.5×+0.4×

Current ratio3.8×-1.0×

Where this comes from

Reported directly by Prime Medicine in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsAndShortTermInvestments.

The official record: Prime Medicine’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Prime Medicine's cash cash equivalents and short term investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Prime Medicine's cash cash equivalents and short term investments?: Prime Medicine (PRME) reported cash cash equivalents and short term investments of $135.5M in Q1 2026.
How has Prime Medicine's cash cash equivalents and short term investments changed year-over-year?: Prime Medicine's cash cash equivalents and short term investments decreased by 6.1% year-over-year, from $144.3M to $135.5M.